Nivolumab,Ipilimumab
BMS
['lung', 'lcsm,(-blcsm)', 'bms', 'bristol', 'bmsnews']
#media: announcing four-year outcomes from our phase 3 dual immunotherapy-based combination trial in metastatic non-small cell #lungcancer to be presented at #asco23. #lcsm 
Patients are our purpose. We come together each day to discover, develop and deliver transformative science to help patients prevail over serious diseases.